Compound Retatrutide: A Research Guide to the Triple-Agonist Peptide

Compound retatrutide is an investigational triple-agonist peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is not FDA-approved for human use, and the material sold online today is a research chemical intended for laboratory work only. No safe or effective human dose has been established outside of controlled clinical trials.

What Is Compound Retatrutide?

Retatrutide is a synthetic peptide developed by Eli Lilly, where it is tracked under the internal code LY3437943. The molecule is engineered as a single chain that binds three separate receptors involved in appetite, blood sugar, and energy expenditure.

When a supplier lists compound retatrutide, it usually means the lyophilized powder form shipped in a sealed vial. The word "compound" describes the finished peptide as prepared and packaged, not a pharmacy-compounded prescription product.

Retatrutide remains an investigational drug. It has no approved indication, no approved labeling, and no established human dosing outside research protocols.

How the Triple-Agonist Mechanism Works

Each receptor retatrutide touches plays a different role in metabolism, and the combination is what sets it apart from older single- and dual-agonist peptides.

Receptor	Primary role	What agonism adds
GLP-1	Appetite and glucose control	Slows gastric emptying, reduces hunger signaling
GIP	Insulin response and fat storage	Improves insulin sensitivity, may enhance fat utilization
Glucagon	Energy expenditure	Increases calorie burning, balanced by GLP-1 activity

Glucagon receptor activity is the unusual part of this profile. Most marketed weight-management peptides avoid glucagon signaling because it raises blood glucose, but retatrutide pairs it with strong GLP-1 and GIP activity, which appears to offset that effect while supporting higher energy expenditure.

What Clinical Research Has Shown So Far

Phase 2 results published in the New England Journal of Medicine reported mean weight reductions of roughly 24% at 48 weeks with the highest weekly dose in adults with obesity. Separate Phase 2 studies have examined retatrutide in type 2 diabetes, knee osteoarthritis pain, and metabolic liver disease.

Eli Lilly has launched a Phase 3 program known as TRIUMPH across obesity, obstructive sleep apnea, knee osteoarthritis, and related conditions. Full Phase 3 results and regulatory review are still pending.

• The most common trial side effects were nausea, diarrhea, vomiting, and constipation.
• Most gastrointestinal effects were mild to moderate and clustered during dose escalation.
• Retatrutide's long-term safety profile is unknown because Phase 3 data have not been released.

These findings describe trial participants under medical supervision. They do not establish a dose that is safe for unsupervised use.

How Retatrutide Compares With Other Research Compounds

Researchers comparing metabolic peptides often line up retatrutide against tirzepatide, semaglutide, and cagrilintide. The table below summarizes the main receptor and status differences.

Compound	Receptor targets	Regulatory status	Notes
Retatrutide	GLP-1, GIP, glucagon	Investigational (Phase 3)	Highest reported weight loss in Phase 2
Tirzepatide	GLP-1, GIP	FDA-approved	Dual agonist, marketed as Mounjaro and Zepbound
Semaglutide	GLP-1	FDA-approved	Single agonist, marketed as Ozempic and Wegovy
Cagrilintide	Amylin	Investigational	Often paired with semaglutide as CagriSema
AOD 9604	hGH fragment 176-191	Research chemical	Studied for fat metabolism, unrelated mechanism

People searching cagrilintide vs retatrutide vs tirzepatide are usually trying to rank them by mechanism and stage of development, and the honest answer is that only tirzepatide has completed regulatory review. Many researchers also look into aod 9604 and retatrutide together when designing studies on fat metabolism, even though the two compounds work through completely separate pathways.

Retatrutide Dosage: What the Trials Used

In the Phase 2 obesity trial, participants started at 2 mg once weekly and stepped up over several weeks to maintenance doses of 4 mg, 8 mg, or 12 mg. Escalation was deliberate because gastrointestinal side effects cluster in the first few weeks.

Those numbers describe a monitored trial protocol, not a recommendation. Self-directed retatrutide dosage is not supported by any published safety data, and the FDA has not reviewed the compound for human use.

What "Research Use Only" Actually Means

Retatrutide sold as a retatrutide research chemical is labeled RUO, which means the seller intends it for in vitro or animal research rather than human consumption. RUO labeling allows a vendor to distribute material that has not been made under drug manufacturing standards.

Buying an RUO retatrutide product does not turn it into a medicine. It comes with no dosing instructions, no sterility assurance, and no FDA oversight, and a certificate of analysis from the seller is not the same as independent third-party testing.

Availability, Brand Name, and Regulatory Timeline

As of 2025, retatrutide is not approved in any country. Analysts generally expect a US decision no earlier than 2027 or 2028 if Phase 3 results support an application, so anyone asking when will retatrutide be available should plan for a multi-year wait.

No retatrutide brand name has been announced. Eli Lilly has not published a trade name, and any product marketed under a branded retatrutide label today is not a genuine approved drug.

Searches for where to buy retatrutide usually land on gray-market peptide sites. Purity across those listings varies widely, and independent testing of research peptides has repeatedly found underdosed or mislabeled vials. Anyone who obtains the compound should talk with a healthcare professional before considering any human use.

Storage, Handling, and Safety Considerations

Research peptides are fragile, and improper handling is one of the most common reasons a vial underperforms in the lab.

• Store lyophilized powder at -20°C or colder, protected from light.
• Refrigerate reconstituted solution at 2-8°C and avoid repeated freeze-thaw cycles.
• Use appropriate personal protective equipment and follow institutional biosafety rules.
• Keep the compound out of reach of children and pets.

Reported side effects in trials include nausea, vomiting, diarrhea, constipation, injection-site reactions, and small increases in heart rate. Pancreatitis and gallbladder events have been reported across the GLP-1 drug class. Anyone with a personal or family history of thyroid cancer, pancreatitis, or gallbladder disease should treat this class of compounds with extra caution and seek medical advice.

COMMON QUESTIONS

Frequently Asked Questions

Is retatrutide FDA approved?

No. Retatrutide is not FDA-approved for any human use in the United States and remains an investigational drug in Phase 3 trials. Any retatrutide sold to consumers is a research chemical labeled for laboratory use only, not an approved medicine with reviewed dosing or safety data.

What is the difference between retatrutide and tirzepatide?

Tirzepatide targets two receptors, GLP-1 and GIP, and is FDA-approved for type 2 diabetes and weight management. Retatrutide adds glucagon receptor activity for a triple-agonist profile, but it is still investigational, so its full efficacy and safety profile has not been confirmed by regulators.

When will retatrutide be available?

Retatrutide is not expected to reach the US market before 2027 or 2028, since it still needs to finish Phase 3 trials and go through FDA review. No brand name has been announced, and no approved version exists anywhere in the world yet.